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Unraveling the Complex Autointoxication of Uremia*Stuart D. Katz, MD,y Chirag R. Parikh, MD, PHDzSEE PAGE 1779“Uremia is a complex auto-intoxication,
the variegated clinical picture being the
summation of the effects of retention of
various urinary constituents.”
— Dr. Arthur Maurice Fishberg,
in Hypertension and Nephritis, 1940 (1)U remia has long been recognized to disruptthe normal physiology of numerous organs,including the heart (2,3). Over the last 30
years, echocardiography studies have found adverse
changes in cardiac structure and function associated
with end-stage renal disease (ESRD), which is collec-
tively termed uremic cardiomyopathy. These cardiac
abnormalities, including left ventricular hypertrophy
and systolic dysfunction, are common in hemodialy-
sis and are associated with an increased risk of
adverse clinical outcomes (4). However, the precise
nature of the uremic mediators of cardiac dysfunction
remain elusive. Kidney transplantation is the treat-
ment of choice for selected patients with ESRD. A suc-
cessful kidney transplantation improves the quality
of life and reduces the mortality risk for most patients
compared with maintenance dialysis (5). However,
50% to 60% of deaths among kidney transplantation
recipients are directly attributable to cardiovascular
disease. In addition, death from cardiovascular*Editorials published in the Journal of the American College of Cardiology
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accounting for 30% of graft loss from death overall
(6). Thus, severe ischemic cardiomyopathy (ejection
fraction [EF] <30%) is a relative contraindication to
kidney transplantation.In this issue of the Journal, Hawwa et al. (7) report
the results of an observational study that describes
the effects of successful kidney transplantation on
cardiac structure and function and predictors of post-
transplantation survival. They retrospectively exam-
ined a cohort of 232 patients with echocardiography
studies available for analysis before and after kidney
transplantation (7). They found that left ventricular
ejection fraction (LVEF) signiﬁcantly increased for
the whole cohort (53% to 56%; p ¼ 0.002), with a
greater magnitude of increase in the 66 patients with
pre-transplantation left ventricular systolic dysfunc-
tion (LVSD) (41% to 50%; p < 0.001). In the group
with pre-transplantation LVSD, the improvement in
EF was accompanied by other signiﬁcant changes
consistent with reverse remodeling, including re-
duced LV end-diastolic dimension, reduced LV mass,
reduced LV wall thickness, and reduced estimated
right ventricular systolic pressure. Although pre-
transplantation LVEF was signiﬁcantly associated
with increased risk of post-transplantation mor-
tality, in the 32 patients with a post-transplantation
increase in EF of $10%, survival was not sig-
niﬁcantly different from that of patients with
normal pre-transplantation systolic function. Hawwa
et al. (7) also found several clinical variables that
were associated with regression of LV mass post-
transplantation, including body mass index, change
in systolic and diastolic blood pressures, and change
in hemoglobin levels. However, only the increase
in hemoglobin levels and estimated glomerular
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better allograft function) were signiﬁcantly associ-
ated with an increase in LVEF. In addition, the rise in
hemoglobin was an independent predictor of post-
transplantation survival.
The observed improvement in LVEF after kidney
transplantation is consistent with previous studies
with serial measurements of cardiac function in kid-
ney transplantation populations (8), previous studies
that investigated the effects of more intense dialysis
on cardiac function (9,10), and experimental results
that have consistently demonstrated the cardiotoxic
effects of uremic serum in single cell preparations,
isolated papillary muscles, and the intact heart
(11–14). The cohort used by Hawwa et al. (7) was larger
than that used in previous reports and included older
subjects, who were more often treated with current
guideline-recommended therapies for LVSD both
before and after transplantation. Interpretation of the
ﬁndings was limited by the observational study
design in a cohort selected on the basis of available
echocardiographic results obtained a median of 422
days after transplantation. This design also intro-
duced immortal time bias because only ﬁtter patients
who survived for 12 to 18 months to undergo post-
transplantation echocardiography were included in
the study. The retrospective observational study de-
sign did not allow inference of a causal relationship
among the reported associations. Nonetheless, when
taken together with previous related studies (8), the
results of this study suggest that ESRD patients
with LVSD should not be routinely excluded from
consideration for kidney transplantation. Additional
investigation is needed to identify clinically useful
predictors of post-transplantation reverse remodeling
and outcomes in dialysis patients with systolic heart
failure.
A novel ﬁnding of the current study is that
the post-transplantation change in hemoglobin
levels was signiﬁcantly associated with a post-
transplantation change in LVEF, and was also in-
dependently associated with post-transplantation
survival after adjustment for EF. In previous reports
with smaller populations, an increase in hemo-
globin (and reversal of other metabolic derangementsassociated with the uremic state) after kidney
transplantation was not signiﬁcantly associated with
a change in LVEF. The observed association be-
tween a change in hemoglobin and survival is
consistent with a large body of literature that has
demonstrated a comparable relationship in non-
dialysis patients with chronic heart failure (15). A
causal association between a change in hemoglobin
and survival seems unlikely, because previous ran-
domized trials have failed to demonstrate survival
beneﬁt of treatment with erythropoietic agents in
anemic patients with heart failure and chronic kidney
disease (16–18). Iron deﬁciency is unlikely a contribu-
tory factor, because intravenous iron supplementation
is routinely administered to promote erythropoiesis
in anemic dialysis populations. Accordingly, the
observed association is likely attributable to other
unmeasured nutritional, metabolic, and clinical fac-
tors associated with the uremic state that affect both
cardiac function and effective erythropoiesis (19).
Hemodilution related to pre-transplantation systolic
heart failure could also contribute to the ﬁndings,
because the observed difference in the hemoglobin
change is driven primarily by the lower pre-
transplantation hemoglobin in these patients (20). It
is also possible that the reported association is a
spurious ﬁnding related to the bias inherent in the
selection of the cohort.
In conclusion, the current study provides an
important contribution to the existing literature
linking improved renal function after successful
kidney transplantation to improved cardiac structure
and function. Additional investigation to charac-
terize the nature of the “complex autointoxication”
associated with uremia might reveal novel thera-
peutic targets to affect reverse LV remodeling,
potentially improving survival in patients with sys-
tolic heart failure and concomitant chronic kidney
disease.
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